Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment CorporationBusiness Wire • 01/10/24
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must WatchSeeking Alpha • 01/10/24
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 01/09/24
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 01/09/24
European Commission Approves Pfizer's TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate CancerBusiness Wire • 01/08/24
Dividend Harvesting Portfolio Week 148: $14,800 Allocated, $1,312.61 In Projected DividendsSeeking Alpha • 01/04/24